Vivos Therapeutics Inc

Company Profile

Vivos Therapeutics Inc had its IPO on 2020-12-11 under the ticker symbol VVOS.

The company operates in the Healthcare sector and Medical Devices industry. Vivos Therapeutics Inc has a staff strength of 154 employees.

Stock update

Shares of Vivos Therapeutics Inc opened at $0.26 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.25 - $0.26, and closed at $0.25.

This is a -1.6% slip from the previous day's closing price.

A total volume of 86,840 shares were traded at the close of the day’s session.

In the last one week, shares of Vivos Therapeutics Inc have slipped by -3.91%.

Vivos Therapeutics Inc's Key Ratios

Vivos Therapeutics Inc has a market cap of $7.66 million, indicating a price to book ratio of 0.4303 and a price to sales ratio of 0.4695.

In the last 12-months Vivos Therapeutics Inc’s revenue was $15.45 million with a gross profit of $12.60 million and an EBITDA of $-20323000. The EBITDA ratio measures Vivos Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Vivos Therapeutics Inc’s operating margin was -135.87% while its return on assets stood at -68.82% with a return of equity of -221.35%.

In Q2, Vivos Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 18.9%.

Vivos Therapeutics Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-0.72 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Vivos Therapeutics Inc’s profitability.

Vivos Therapeutics Inc stock is trading at a EV to sales ratio of 0.0765 and a EV to EBITDA ratio of 0.2893. Its price to sales ratio in the trailing 12-months stood at 0.4695.

Vivos Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$13.75 million

Total Liabilities

$8.44 million

Operating Cash Flow

$0

Capital Expenditure

$245000

Dividend Payout Ratio

0%

Vivos Therapeutics Inc ended 2024 with $13.75 million in total assets and $0 in total liabilities. Its intangible assets were valued at $13.75 million while shareholder equity stood at $2.11 million.

Vivos Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $8.44 million in other current liabilities, 3000.00 in common stock, $-86699000.00 in retained earnings and $2.84 million in goodwill. Its cash balance stood at $3.94 million and cash and short-term investments were $3.94 million. The company’s total short-term debt was $447,000 while long-term debt stood at $0.

Vivos Therapeutics Inc’s total current assets stands at $5.34 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $327000.00 compared to accounts payable of $1.33 million and inventory worth $0.

In 2024, Vivos Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $245000.

Comparatively, Vivos Therapeutics Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price

$0.25

52-Week High

$2.25

52-Week Low

$0.23

Analyst Target Price

$1.8

Vivos Therapeutics Inc stock is currently trading at $0.25 per share. It touched a 52-week high of $2.25 and a 52-week low of $2.25. Analysts tracking the stock have a 12-month average target price of $1.8.

Its 50-day moving average was $0.32 and 200-day moving average was $0.53 The short ratio stood at 0.28 indicating a short percent outstanding of 0%.

Around 1693.4% of the company’s stock are held by insiders while 1669.1% are held by institutions.